Alterations of eicosanoids and related mediators in patients with schizophrenia

Dongfang Wang, Xiaoyu Sun, Jingjing Yan, Biao Ren, Bing Cao, Qingbin Lu, Yaqiong Liu, Jing Zeng, Ninghua Huang, Qing Xie, Haiwei Gu, Jingyu Wang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Schizophrenia (SCZ) is a multifactorial psychiatric disorder. Currently, its molecular pathogenesis remains largely unknown, and no reliable test for diagnosis and therapy monitoring is available. Polyunsaturated fatty acids (PUFAs) and their derived eicosanoid signaling abnormalities are relevant to the pathophysiology of schizophrenia. However, comprehensive analysis of eicosanoids and related mediators for schizophrenia is very rare. In this study, we applied a targeted liquid chromatography-mass spectrometry based method to monitor 158 PUFAs, eicosanoids and related mediators from enzyme-dependent or independent pathways, in the serum samples of 109 healthy controls, and 115 schizophrenia patients at baseline and after an 8-week period of antipsychotic therapy. Twenty-three metabolites were identified to be significantly altered in SCZ patients at baseline compared to healthy controls, especially arachidonic acid (AA) derived eicosanoids. These disturbances may be related to altered immunological reactions and neurotransmitter signaling. After 8-week antipsychotic treatment, there were 22 metabolites, especially AA and linoleic acid derived eicosanoids, significantly altered in posttreatment patients. Some metabolites, such as several AA derived prostaglandins, thromboxanes, and di-hydroxy-eicosatrienoic acids were reversed toward normal levels after treatment. Based on univariate analysis and orthogonal partial least-squares discriminant analysis, anandamide, oleoylethanolamine, and AA were selected as a panel of potential biomarkers for differentiating baseline SCZ patients from controls, which showed a high sensitivity (0.907), good specificity (0.843) and excellent area under the receiver operating characteristic curve (0.940). This study provided a new perspective to understand the pathophysiological mechanism and identify potential biomarkers of SCZ.

Original languageEnglish (US)
Pages (from-to)168-178
Number of pages11
JournalJournal of Psychiatric Research
Volume102
DOIs
StatePublished - Jul 1 2018

Fingerprint

Eicosanoids
Schizophrenia
Arachidonic Acid
Unsaturated Fatty Acids
Antipsychotic Agents
Biomarkers
Hydroxy Acids
Thromboxanes
Discriminant Analysis
Linoleic Acid
Therapeutics
Least-Squares Analysis
ROC Curve
Liquid Chromatography
Prostaglandins
Neurotransmitter Agents
Psychiatry
Mass Spectrometry
Enzymes
Serum

Keywords

  • Biomarker
  • Eicosanoids
  • Liquid chromatography-mass spectrometry
  • Metabolomics
  • Polyunsaturated fatty acids
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Alterations of eicosanoids and related mediators in patients with schizophrenia. / Wang, Dongfang; Sun, Xiaoyu; Yan, Jingjing; Ren, Biao; Cao, Bing; Lu, Qingbin; Liu, Yaqiong; Zeng, Jing; Huang, Ninghua; Xie, Qing; Gu, Haiwei; Wang, Jingyu.

In: Journal of Psychiatric Research, Vol. 102, 01.07.2018, p. 168-178.

Research output: Contribution to journalArticle

Wang, D, Sun, X, Yan, J, Ren, B, Cao, B, Lu, Q, Liu, Y, Zeng, J, Huang, N, Xie, Q, Gu, H & Wang, J 2018, 'Alterations of eicosanoids and related mediators in patients with schizophrenia', Journal of Psychiatric Research, vol. 102, pp. 168-178. https://doi.org/10.1016/j.jpsychires.2018.04.002
Wang, Dongfang ; Sun, Xiaoyu ; Yan, Jingjing ; Ren, Biao ; Cao, Bing ; Lu, Qingbin ; Liu, Yaqiong ; Zeng, Jing ; Huang, Ninghua ; Xie, Qing ; Gu, Haiwei ; Wang, Jingyu. / Alterations of eicosanoids and related mediators in patients with schizophrenia. In: Journal of Psychiatric Research. 2018 ; Vol. 102. pp. 168-178.
@article{d6187f81564d48c4ae3cc8a611c2f7e8,
title = "Alterations of eicosanoids and related mediators in patients with schizophrenia",
abstract = "Schizophrenia (SCZ) is a multifactorial psychiatric disorder. Currently, its molecular pathogenesis remains largely unknown, and no reliable test for diagnosis and therapy monitoring is available. Polyunsaturated fatty acids (PUFAs) and their derived eicosanoid signaling abnormalities are relevant to the pathophysiology of schizophrenia. However, comprehensive analysis of eicosanoids and related mediators for schizophrenia is very rare. In this study, we applied a targeted liquid chromatography-mass spectrometry based method to monitor 158 PUFAs, eicosanoids and related mediators from enzyme-dependent or independent pathways, in the serum samples of 109 healthy controls, and 115 schizophrenia patients at baseline and after an 8-week period of antipsychotic therapy. Twenty-three metabolites were identified to be significantly altered in SCZ patients at baseline compared to healthy controls, especially arachidonic acid (AA) derived eicosanoids. These disturbances may be related to altered immunological reactions and neurotransmitter signaling. After 8-week antipsychotic treatment, there were 22 metabolites, especially AA and linoleic acid derived eicosanoids, significantly altered in posttreatment patients. Some metabolites, such as several AA derived prostaglandins, thromboxanes, and di-hydroxy-eicosatrienoic acids were reversed toward normal levels after treatment. Based on univariate analysis and orthogonal partial least-squares discriminant analysis, anandamide, oleoylethanolamine, and AA were selected as a panel of potential biomarkers for differentiating baseline SCZ patients from controls, which showed a high sensitivity (0.907), good specificity (0.843) and excellent area under the receiver operating characteristic curve (0.940). This study provided a new perspective to understand the pathophysiological mechanism and identify potential biomarkers of SCZ.",
keywords = "Biomarker, Eicosanoids, Liquid chromatography-mass spectrometry, Metabolomics, Polyunsaturated fatty acids, Schizophrenia",
author = "Dongfang Wang and Xiaoyu Sun and Jingjing Yan and Biao Ren and Bing Cao and Qingbin Lu and Yaqiong Liu and Jing Zeng and Ninghua Huang and Qing Xie and Haiwei Gu and Jingyu Wang",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.jpsychires.2018.04.002",
language = "English (US)",
volume = "102",
pages = "168--178",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Alterations of eicosanoids and related mediators in patients with schizophrenia

AU - Wang, Dongfang

AU - Sun, Xiaoyu

AU - Yan, Jingjing

AU - Ren, Biao

AU - Cao, Bing

AU - Lu, Qingbin

AU - Liu, Yaqiong

AU - Zeng, Jing

AU - Huang, Ninghua

AU - Xie, Qing

AU - Gu, Haiwei

AU - Wang, Jingyu

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Schizophrenia (SCZ) is a multifactorial psychiatric disorder. Currently, its molecular pathogenesis remains largely unknown, and no reliable test for diagnosis and therapy monitoring is available. Polyunsaturated fatty acids (PUFAs) and their derived eicosanoid signaling abnormalities are relevant to the pathophysiology of schizophrenia. However, comprehensive analysis of eicosanoids and related mediators for schizophrenia is very rare. In this study, we applied a targeted liquid chromatography-mass spectrometry based method to monitor 158 PUFAs, eicosanoids and related mediators from enzyme-dependent or independent pathways, in the serum samples of 109 healthy controls, and 115 schizophrenia patients at baseline and after an 8-week period of antipsychotic therapy. Twenty-three metabolites were identified to be significantly altered in SCZ patients at baseline compared to healthy controls, especially arachidonic acid (AA) derived eicosanoids. These disturbances may be related to altered immunological reactions and neurotransmitter signaling. After 8-week antipsychotic treatment, there were 22 metabolites, especially AA and linoleic acid derived eicosanoids, significantly altered in posttreatment patients. Some metabolites, such as several AA derived prostaglandins, thromboxanes, and di-hydroxy-eicosatrienoic acids were reversed toward normal levels after treatment. Based on univariate analysis and orthogonal partial least-squares discriminant analysis, anandamide, oleoylethanolamine, and AA were selected as a panel of potential biomarkers for differentiating baseline SCZ patients from controls, which showed a high sensitivity (0.907), good specificity (0.843) and excellent area under the receiver operating characteristic curve (0.940). This study provided a new perspective to understand the pathophysiological mechanism and identify potential biomarkers of SCZ.

AB - Schizophrenia (SCZ) is a multifactorial psychiatric disorder. Currently, its molecular pathogenesis remains largely unknown, and no reliable test for diagnosis and therapy monitoring is available. Polyunsaturated fatty acids (PUFAs) and their derived eicosanoid signaling abnormalities are relevant to the pathophysiology of schizophrenia. However, comprehensive analysis of eicosanoids and related mediators for schizophrenia is very rare. In this study, we applied a targeted liquid chromatography-mass spectrometry based method to monitor 158 PUFAs, eicosanoids and related mediators from enzyme-dependent or independent pathways, in the serum samples of 109 healthy controls, and 115 schizophrenia patients at baseline and after an 8-week period of antipsychotic therapy. Twenty-three metabolites were identified to be significantly altered in SCZ patients at baseline compared to healthy controls, especially arachidonic acid (AA) derived eicosanoids. These disturbances may be related to altered immunological reactions and neurotransmitter signaling. After 8-week antipsychotic treatment, there were 22 metabolites, especially AA and linoleic acid derived eicosanoids, significantly altered in posttreatment patients. Some metabolites, such as several AA derived prostaglandins, thromboxanes, and di-hydroxy-eicosatrienoic acids were reversed toward normal levels after treatment. Based on univariate analysis and orthogonal partial least-squares discriminant analysis, anandamide, oleoylethanolamine, and AA were selected as a panel of potential biomarkers for differentiating baseline SCZ patients from controls, which showed a high sensitivity (0.907), good specificity (0.843) and excellent area under the receiver operating characteristic curve (0.940). This study provided a new perspective to understand the pathophysiological mechanism and identify potential biomarkers of SCZ.

KW - Biomarker

KW - Eicosanoids

KW - Liquid chromatography-mass spectrometry

KW - Metabolomics

KW - Polyunsaturated fatty acids

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85045548778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045548778&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychires.2018.04.002

DO - 10.1016/j.jpsychires.2018.04.002

M3 - Article

VL - 102

SP - 168

EP - 178

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

ER -